Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Until very recently, all available guidelines for the early assessment of risk for prostate cancer clearly recommended the use of a physical examination (a digital rectal exam or DRE) in addition to a prostate-specific antigen (PSA) test.
Filed under: Diagnosis, Risk | Tagged: digital rectal examination, DRE, guideline, PSA, risk | 1 Comment »
A new report just published as an open access, full-text article at BMJ.com is going to further confuse the issue of whether mass, population-based screening for prostate cancer is or isn’t a good idea.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: DRE, mortality, Norrkoping, outcome, PSA, screening, Sweden | 14 Comments »
A new review by specialists from Erasmus University Medical Center, just published in Prostate Cancer and Prostatic Diseases, states categorically that mass, population-based screening for prostate cancer “cannot be justified yet in the context of a public health policy.”
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: DRE, population-based, PSA, risk, screening | 22 Comments »
A new article in the Australian Medical Journal is titled, “It’s time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials.” We think this article makes a lot of sense.
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, screening, testing | 1 Comment »
In today’s news reports we cover items on: Risks for prostate cancer from smoking and increased adipose tissue The role of religious activities in prostate cancer testing among African Americans Blood loss at the time of surgery and risk for progressive disease
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: adipose, blood loss, BMI, body mass index, DRE, ethnicity, recurrence, religion, risk, smoking | Leave a Comment »
This morning’s news reports address: Patterns of use of PSA and DRE testing in the USA The value of ADT in men receiving combined brachytherapy + EBRT Skeletal and cardiovascular adverse effects of ADT LHRH agonist treatment and effects on LHRH agonist receptors
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, DRE, LHRH agonist, mechanism of action, pattens of use, PSA | Leave a Comment »
Even though many medical organizations recommend discussions between patients and their doctors before testing of individuals for risk of prostate cancer, there are few hard data about how primary care physicians (PCPs) actually apply thee guidelines to promote informed decision making for prostate cancer testing.
Filed under: Diagnosis, Risk | Tagged: DRE, PCP, primary care physician, PSA, screening, testing | Leave a Comment »
… a paper from the University of Texas Health Sciences Center in San Antonio has provided a detailed analysis of the spectrum of variation of PSA and DRE data among men in an earlier screening program.
Filed under: Diagnosis, Risk | Tagged: changes over time, DRE, PSA, screening | 3 Comments »
Many readers may be interested in seeing what Johns Hopkins has to say about the two studies published just over a week ago in the New England Journal of Medicine. This topic is addressed under the heading “Recent PSA Studies: What You Need To Know” in the latest issue of Health Alerts. Interestingly, in this [...]
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, risk, screening | 1 Comment »
We thought it might be wise to make sure that readers of The “New” Prostate Cancer InfoLink didn’t just hear what we thought about today’s two NEJM articles, but also got a cross-section of perspectives from others. Where relevant we have taken the liberty of giving our opinion on the articles we think you might [...]
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, screening | 1 Comment »
As we have already, albeit briefly, reported, two “major” papers were published in the New England Journal of Medicine today, and they both were designed to address the appropriateness of mass screening for prostate cancer — among men over the age of 55 years in the USA and over 50 years in Europe respectively. We [...]
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, randomized trial, screening | 11 Comments »
There are six reports in the news for the weekend, addressing such topics as: DRE for prostate cancer at the time of colonoscopy Development of a 3D transrectal ultrasound-guided biopsy system False-positive biochemical failures after external beam radiotherapy Activity of inactivated Sendai virus particles on HRPC in vitro Male pattern baldness, serum androgen levels, and [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: 3D transrectal ultrasound, baldness, biopsy, colonoscopy, DRE, gynecomastia, Sendai virus | Leave a Comment »
Today’s news reports are focused on issued around epidemiology, prevention, diagnosis, treatment decisions, and the role of humor in prostate cancer support group interactions.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active surveillance, arsenic, DRE, finasteride, humor, masculinity, Prevention, support groups | Leave a Comment »
Today’s reports include items on: Perceptions of pain and discomfort in men undergoing DRE 10-year survival data of men with pT3 disease treated initially with a radical prostatectomy Orchiectomy, medical castration, and acceptable social costs Hemi-body radiation to treat pain in men with multiple bone metastases
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: castration, DRE, hemi-body radiation, orchiectomy, stage T3 disease | Leave a Comment »
Todays’ reports contain some interesting data, although it is not entirely clear how they should best be applied in the diagnosis and potential management of patients at risk: A study of patient preferences and decision making about how to be treated Why some Brazilian men reject digital rectal examination (fewer that you might expect) The [...]
Filed under: Diagnosis, Management | Tagged: cancer, Combidex, DRE, ferumoxtran-10, HGPIN, news, preferences, prostate, update | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site